JP2017537972A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537972A5
JP2017537972A5 JP2017538182A JP2017538182A JP2017537972A5 JP 2017537972 A5 JP2017537972 A5 JP 2017537972A5 JP 2017538182 A JP2017538182 A JP 2017538182A JP 2017538182 A JP2017538182 A JP 2017538182A JP 2017537972 A5 JP2017537972 A5 JP 2017537972A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
seq
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017538182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537972A (ja
JP6795505B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/054202 external-priority patent/WO2016057488A1/en
Publication of JP2017537972A publication Critical patent/JP2017537972A/ja
Publication of JP2017537972A5 publication Critical patent/JP2017537972A5/ja
Application granted granted Critical
Publication of JP6795505B2 publication Critical patent/JP6795505B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017538182A 2014-10-06 2015-10-06 ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 Active JP6795505B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060381P 2014-10-06 2014-10-06
US62/060,381 2014-10-06
PCT/US2015/054202 WO2016057488A1 (en) 2014-10-06 2015-10-06 Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020138331A Division JP7129449B2 (ja) 2014-10-06 2020-08-19 ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法

Publications (3)

Publication Number Publication Date
JP2017537972A JP2017537972A (ja) 2017-12-21
JP2017537972A5 true JP2017537972A5 (https=) 2018-11-15
JP6795505B2 JP6795505B2 (ja) 2020-12-02

Family

ID=54337425

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017538182A Active JP6795505B2 (ja) 2014-10-06 2015-10-06 ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
JP2020138331A Active JP7129449B2 (ja) 2014-10-06 2020-08-19 ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
JP2022131610A Active JP7589204B2 (ja) 2014-10-06 2022-08-22 ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020138331A Active JP7129449B2 (ja) 2014-10-06 2020-08-19 ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
JP2022131610A Active JP7589204B2 (ja) 2014-10-06 2022-08-22 ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法

Country Status (7)

Country Link
US (4) US10675349B2 (https=)
EP (2) EP3204418B1 (https=)
JP (3) JP6795505B2 (https=)
CN (2) CN107250160B (https=)
AU (2) AU2015328273B2 (https=)
CA (1) CA2962949C (https=)
WO (1) WO2016057488A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6795505B2 (ja) * 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
BR112017013176A2 (en) 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
EP3288977B1 (en) 2015-05-01 2021-11-17 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3508206A4 (en) * 2016-09-01 2020-04-29 Bebeachibuli, Romeo Food factor-based formulation, products produced using said formulation and methods for producing same
JP7269167B2 (ja) 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
AU2019235900B2 (en) 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same
JP7277255B2 (ja) * 2018-05-31 2023-05-18 佳寛 大矢 インビトロでの制御性ｔ細胞の特異性評価方法
WO2020113224A2 (en) 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
EP3927731A4 (en) * 2019-02-19 2022-12-28 The Regents of the University of Colorado, a body corporate BISPECIFIC IMMUNOTOXINS FOR TARGETING HUMAN CD25S-CCR4+ TUMORS AND REGULATORY T-CELLS
AU2020253060B2 (en) * 2019-03-29 2025-09-25 Universität Zürich Fc-modified biologicals for local delivery to compartments, in particular to the CNS
CN114051532A (zh) * 2019-05-24 2022-02-15 希望之城公司 用于治疗ccr4阳性恶性肿瘤的经ccr4靶向性嵌合抗原受体修饰的t细胞
AU2020290579B2 (en) 2019-06-14 2026-02-12 Dana-Farber Cancer Institute, Inc. Antibodies against MUC1 and methods of use thereof
CN111704668B (zh) * 2020-06-27 2021-03-30 天津金域医学检验实验室有限公司 抗ccr4抗体及其在治疗癌症中的应用
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
GB8426467D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993004701A1 (en) 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CN100455599C (zh) * 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
JP2003208610A (ja) 2002-01-16 2003-07-25 Noritsu Koki Co Ltd 画像処理装置、画像処理方法、画像処理プログラム、および画像処理プログラムを記録した記録媒体
US20070172476A1 (en) * 2005-07-28 2007-07-26 Kyowa Hakko Kogyo Co., Ltd. Method of treating B-cell neoplasms or Hodgkin's lymphoma
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
GB201020738D0 (en) * 2010-12-07 2011-01-19 Affitech Res As Antibodies
AU2013256010B2 (en) * 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
JP6795505B2 (ja) * 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法

Similar Documents

Publication Publication Date Title
JP2017537972A5 (https=)
JP2020193210A5 (https=)
JP2022159548A5 (https=)
Liu et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Kirtane et al. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
Duan et al. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma
Ha et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
Lian et al. Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors
Baysal et al. The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies
JP2020127426A5 (https=)
Boettcher et al. Development of CAR T cell therapy in children—A comprehensive overview
JP2015517470A5 (https=)
JP2020103301A5 (https=)
BR112021007626A2 (pt) Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
US20220380468A1 (en) Modulation of immune response using btla agonist antibodies
JP2019513777A5 (https=)
JP2020503891A5 (https=)
JP2018508483A5 (https=)
JP2017531427A5 (https=)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2018517415A5 (https=)
JP2018529327A5 (https=)
CN117285642A (zh) 制导和导航控制蛋白及其制备和使用方法
JPWO2019173324A5 (https=)
JP2014526898A5 (https=)